| Measuring progress from 1990 to 2017 and projecting attainment to 2030 of the health-related Sustainable Development Goals for 195 countries and territories: a systematic … R Lozano, N Fullman, D Abate, SM Abay, C Abbafati, N Abbasi, ... The lancet 392 (10159), 2091-2138, 2018 | 535 | 2018 |
| Systemic complement activation is associated with respiratory failure in COVID-19 hospitalized patients JC Holter, SE Pischke, E de Boer, A Lind, S Jenum, AR Holten, K Tonby, ... Proceedings of the National Academy of Sciences 117 (40), 25018-25025, 2020 | 365 | 2020 |
| Humoral and cellular immune responses to two and three doses of SARS-CoV-2 vaccines in rituximab-treated patients with rheumatoid arthritis: a prospective, cohort study I Jyssum, H Kared, TT Tran, AT Tveter, SA Provan, J Sexton, ... The Lancet Rheumatology 4 (3), e177-e187, 2022 | 151 | 2022 |
| Evaluation of the effects of remdesivir and hydroxychloroquine on viral clearance in COVID-19: a randomized trial A Barratt-Due, IC Olsen, K Nezvalova-Henriksen, T Kåsine, ... Annals of internal medicine 174 (9), 1261-1269, 2021 | 138 | 2021 |
| Immunogenicity and safety of a third SARS-CoV-2 vaccine dose in patients with multiple sclerosis and weak immune response after COVID-19 vaccination M König, HM Torgauten, T Holmøy, JT Vaage, F Lund-Johansen, ... JAMA neurology 79 (3), 307-309, 2022 | 79 | 2022 |
| Tixagevimab–cilgavimab for treatment of patients hospitalised with COVID-19: a randomised, double-blind, phase 3 trial TL Holland, AA Ginde, R Paredes, TA Murray, N Engen, G Grandits, ... The Lancet Respiratory Medicine 10 (10), 972-984, 2022 | 72 | 2022 |
| Immune responses in Omicron SARS-CoV-2 breakthrough infection in vaccinated adults H Kared, AS Wolf, A Alirezaylavasani, A Ravussin, G Solum, TT Tran, ... Nature communications 13 (1), 4165, 2022 | 62 | 2022 |
| Spatial-proteomics reveals phospho-signaling dynamics at subcellular resolution A Martinez-Val, DB Bekker-Jensen, S Steigerwald, C Koenig, ... Nature communications 12 (1), 7113, 2021 | 60 | 2021 |
| Humoral immunity to SARS-CoV-2 mRNA vaccination in multiple sclerosis: the relevance of time since last rituximab infusion and first experience from sporadic revaccinations M König, ÅR Lorentzen, HM Torgauten, S Schikora-Rustad, EB Vaage, ... Journal of Neurology, Neurosurgery & Psychiatry 94 (1), 19-22, 2023 | 57 | 2023 |
| Immunogenicity and Safety of Standard and Third‐Dose SARS–CoV‐2 Vaccination in Patients Receiving Immunosuppressive Therapy SW Syversen, I Jyssum, AT Tveter, TT Tran, J Sexton, SA Provan, ... Arthritis & Rheumatology 74 (8), 1321-1332, 2022 | 51 | 2022 |
| Persistent pulmonary pathology after COVID-19 is associated with high viral load, weak antibody response, and high levels of matrix metalloproteinase-9 TV Lerum, NN Maltzahn, P Aukrust, M Trøseid, KN Henriksen, T Kåsine, ... Scientific Reports 11 (1), 23205, 2021 | 37 | 2021 |
| Rituximab‐treated patients with lymphoma develop strong CD8 T‐cell responses following COVID‐19 vaccination J Riise, S Meyer, I Blaas, A Chopra, TT Tran, M Delic‐Sarac, ... British journal of haematology 197 (6), 697-708, 2022 | 31 | 2022 |
| Titers of antibodies against ancestral SARS-CoV-2 correlate with levels of neutralizing antibodies to multiple variants TT Tran, EB Vaage, A Mehta, A Chopra, L Tietze, A Kolderup, A Anthi, ... npj Vaccines 7 (1), 174, 2022 | 28 | 2022 |
| Prevalent and immunodominant CD8 T cell epitopes are conserved in SARS-CoV-2 variants S Meyer, I Blaas, RC Bollineni, M Delic-Sarac, TT Tran, C Knetter, KZ Dai, ... Cell reports 42 (1), 2023 | 25 | 2023 |
| Immunogenicity and safety of a three-dose SARS-CoV-2 vaccination strategy in patients with immune-mediated inflammatory diseases on immunosuppressive therapy SW Syversen, I Jyssum, AT Tveter, J Sexton, IE Christensen, TT Tran, ... RMD open 8 (2), e002417, 2022 | 24 | 2022 |
| Four SARS-CoV-2 vaccine doses or hybrid immunity in patients on immunosuppressive therapies: a Norwegian cohort study KH Bjørlykke, HS Ørbo, AT Tveter, I Jyssum, J Sexton, TT Tran, ... The Lancet Rheumatology 5 (1), e36-e46, 2023 | 23 | 2023 |
| Low immunization rate in kidney transplant recipients also after dose 2 of the BNT162b2 vaccine: continue to keep your guard up! K Midtvedt, T Tran, K Parker, HP Marti, AE Stenehjem, LG Gøransson, ... Transplantation 105 (8), e80-e81, 2021 | 21 | 2021 |
| The persistence of anti-Spike antibodies following two SARS-CoV-2 vaccine doses in patients on immunosuppressive therapy compared to healthy controls—a prospective cohort study IE Christensen, I Jyssum, AT Tveter, J Sexton, TT Tran, S Mjaaland, ... BMC medicine 20 (1), 378, 2022 | 16 | 2022 |
| Breakthrough infections with the omicron and delta variants of SARS-CoV-2 result in similar re-activation of vaccine-induced immunity A Søraas, G Grødeland, BK Granerud, T Ueland, A Lind, B Fevang, ... Frontiers in immunology 13, 964525, 2022 | 16 | 2022 |
| AT cell receptor targeting a recurrent driver mutation in FLT3 mediates elimination of primary human acute myeloid leukemia in vivo E Giannakopoulou, M Lehander, S Virding Culleton, W Yang, Y Li, ... Nature Cancer 4 (10), 1474-1490, 2023 | 15 | 2023 |